Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xalatan First-line in Naive OH/OAG
NCT00647101Phase 4Completed
- Sponsor
- Viatris
- Start
- Dec 2003
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of latanoprost in ocular hypertension and open-angle glaucoma (OAG), sponsored by Viatris. Primary endpoint: Change in Intraocular Pressure (absolute values) at 3 months. Started Dec 2003; status: completed.
02
Drugs
latanoprost
03
Conditions
ocular hypertensionopen-angle glaucoma (OAG)
Beyond the preview
Go deeper on NCT00647101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00647101.